Edition:
United Kingdom

argenx SE (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

84.94USD
17 Aug 2018
Change (% chg)

$1.29 (+1.54%)
Prev Close
$83.65
Open
$83.76
Day's High
$84.94
Day's Low
$82.99
Volume
25,559
Avg. Vol
24,978
52-wk High
$103.00
52-wk Low
$20.35

Latest Key Developments (Source: Significant Developments)

Argenx Receives Milestone Payment From Strategic Collaboration With Shire
Tuesday, 17 Jul 2018 

July 17 (Reuters) - ARGENX SE ::REG-ARGENX RECEIVES MILESTONE PAYMENT FROM STRATEGIC COLLABORATION WITH SHIRE.HAS REACHED A PRECLINICAL MILESTONE IN ITS STRATEGIC COLLABORATION WITH SHIRE PLC.MILESTONE TRIGGERED BY SHIRE EXERCISING OPTION TO IN-LICENSE AN ANTIBODY DISCOVERED AND DEVELOPED USING CO'S SIMPLE ANTIBODY PLATFORM AND FC ENGINEERING TECHNOLOGIES.  Full Article

Argenx SE Says Euronext Has Selected Argenx SE For Inclusion In BEL 20 Index On Euronext Brussels
Tuesday, 5 Jun 2018 

June 5 (Reuters) - argenx SE ::ARGENX SE SAYS EURONEXT HAS SELECTED ARGENX SE FOR INCLUSION IN BEL 20 INDEX ON EURONEXT BRUSSELS, EFFECTIVE JUNE 18, 2018.  Full Article

Argenx SE Files For Potential Mixed Shelf Offering
Friday, 1 Jun 2018 

June 1 (Reuters) - argenx SE ::ARGENX SE FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Argenx Q1 Operating Income Down At 6.9 Million Euros
Wednesday, 9 May 2018 

May 9 (Reuters) - ARGENX NV ::ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 OPERATING INCOME OF EUR 6.9 MILLION (MARCH 31, 2017: EUR 7.2 MILLION)..Q1 TOTAL COMPREHENSIVE LOSS OF EUR 17.7 MILLION (MARCH 31, 2017: EUR 8.4 MILLION).CASH POSITION OF EUR 346.6 MILLION (MARCH 31, 2017: EUR 85.0 MILLION).EXPECTED MILESTONE: PROGRESS ARGX-113 INTO PHASE 3 CLINICAL DEVELOPMENT IN GENERALIZED MG BEFORE END OF YEAR.  Full Article

Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)
Tuesday, 24 Apr 2018 

April 24 (Reuters) - ARGENX NV ::REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING.EIGHT-WEEK FOLLOW-UP DATA SHOW SEPARATION OF CLINICAL EFFICACY SCORES BETWEEN TREATMENT GROUP AND PLACEBO GROUP THROUGH DURATION OF STUDY.TOTAL AND PATHOGENIC IGG REDUCTION CORRELATES WITH DISEASE SCORE IMPROVEMENTS.  Full Article

Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma
Thursday, 12 Apr 2018 

April 12 (Reuters) - ARGENX ::TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX .AS PART OF AGREEMENT, ARGENX HAS GRANTED LEO PHARMA AN EXCLUSIVE OPTION TO OBTAIN A WORLDWIDE, EXCLUSIVE LICENSE TO ARGX-112 PROGRAM,.ARGX-112 PROGRAM AIMS TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS FOR INFLAMMATORY SKIN DISORDERS.MAY RECEIVE FURTHER REGULATORY AND CLINICAL MILESTONE PAYMENTS UP TO APPROX. EUR 100MM AS WELL AS ROYALTIES ON NET SALES OF ANY PRODUCT.  Full Article

BRIEF-Argenx: Publication Of Study Results From Phase 1 Of FcRn-Antagonist Efgartigimod

* ANNOUNCED ON TUESDAY PUBLICATION OF FULL STUDY RESULTS FROM PHASE 1 OF FCRN-ANTAGONIST EFGARTIGIMOD (ARGX-113) IN HEALTHY VOLUNTEERS